Weight Management

A network meta-analysis compared medications for weight reduction in antipsychotic-treated schizophrenia spectrum disorders.

An integrated UK Biobank and preclinical study linked obesity-related metabolic inflammation to PTPN11-mutant myeloid leukemia and found that combined GLP-1R agonism and IL-17A blockade reduced leukemic...

A 2-year trial compared tirzepatide with intensified conventional care in adults with early type 2 diabetes.

Researchers assessed whether GLP-1 exposure was associated with breast cancer incidence among women undergoing screening.

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...

April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

Post hoc subgroup analysis of interim phase 3 data shows weight loss with atogepant in migraine and overweight or obesity.

The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.